Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy

British Journal of Cancer

Volumn 86, Issue 6, 2002, Pages 1017-1018

  Andres, R ^a   Mayordomo, J I ^a   Isla, D ^a   Marti, J L ^a   Escudero, P ^a   Filipovich, E ^a   Saenz, A ^a   Alvarez, I ^a   Polo, E ^a   Tres, A ^a  

^a Hospital Universitario   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; NAVELBINE; THIOTEPA;

ADULT; AGED; ALOPECIA; ANEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; LETTER; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 18344392050     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600164     Document Type: Letter

References (9)

1. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy
2. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel
3. Durable response in metastatic breast cancer with high-dose paclitaxel in combination with cyclophosphamide, carboplatin, thiotepa and stem cell rescue
4. High-dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: Results of the French Protocol PEGASE 04
5. Phase I trial of high-dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue
6. Reporting results of cancer treatment
7. Phase II Randomized Trial of High-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methrotrexate and 5-fluoracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The 'Philadelphia' Intergroup Study (PBT-1)
8. Phase II study of weekly paclitaxel treatment in recurrent breast cancer after high-dose chemotherapy
9. Oral capecitabine is active and well tolerated in patients with metastatic breast cancer who progress after high dose chemotherapy and autologous stem cell support